吡嗪-2-羰基叠氮化物 | 75322-66-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 吡嗪-2-羰基叠氮化物
• 英文名称: pyrazine-2-carbonyl azide
• 英文别名: 2-pyrazinoyl azide；2-pyrazine-carboxylic acid azide；pyrazine-2-carbonylazide；Pyrazin-2-carbonsaeureazid
• CAS: 75322-66-6
• 化学式: C₅H₃N₅O
• mdl: MFCD20484520
• 分子量: 149.112
• InChiKey: RLNGGCZBYFRNSV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  57.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  吡嗪-2-羰基叠氮化物 以 甲苯 为溶剂， 反应 1.0h， 生成 2-pyrazineisocyanate
  参考文献：
  名称：

  Novel Tetrahydropyrido[1,2-a]isoindolone Derivatives (Valmerins): Potent Cyclin-Dependent Kinase/Glycogen Synthase Kinase 3 Inhibitors with Antiproliferative Activities and Antitumor Effects in Human Tumor Xenografts

  摘要：

  The development of CDK and GSK3 inhibitors has been regarded as a potential therapeutic approach, and a substantial number-of-diverse structures have been reported to inhibit CDKs and GSK-3 beta. in recent years. Only a few molecules have gone through or are currently undergoing clinical trials as CDK and GSK inhibitors. In this paper, we prepared valmerins, a new family containing the tetrahydropyrido[1,2-a]isoindone core. The fused heterocycle was prepared with a straightforward synthesis that was functionalized by a (het)arylurea. Twelve valmerins inhibited the CDK5 and GSK3 with an IC50 < 100 nM. A semiquantitative kinase scoring was realized, and a cellular screening was done. At the end of study, we investigated the in vivo potency of one valmerin. Mice exhibited good tolerance to our lead, which proved its efficacy and clearly blocked tumor growth. Valmerins appear also as good candidates: for further development as anticancer agents.

  DOI：

  10.1021/jm3008536
• 作为产物：
  描述：

  吡嗪-2-甲酰氯 在 sodium azide 作用下， 以 水 为溶剂， 反应 1.0h， 生成 吡嗪-2-羰基叠氮化物
  参考文献：
  名称：

  Novel Tetrahydropyrido[1,2-a]isoindolone Derivatives (Valmerins): Potent Cyclin-Dependent Kinase/Glycogen Synthase Kinase 3 Inhibitors with Antiproliferative Activities and Antitumor Effects in Human Tumor Xenografts

  摘要：

  The development of CDK and GSK3 inhibitors has been regarded as a potential therapeutic approach, and a substantial number-of-diverse structures have been reported to inhibit CDKs and GSK-3 beta. in recent years. Only a few molecules have gone through or are currently undergoing clinical trials as CDK and GSK inhibitors. In this paper, we prepared valmerins, a new family containing the tetrahydropyrido[1,2-a]isoindone core. The fused heterocycle was prepared with a straightforward synthesis that was functionalized by a (het)arylurea. Twelve valmerins inhibited the CDK5 and GSK3 with an IC50 < 100 nM. A semiquantitative kinase scoring was realized, and a cellular screening was done. At the end of study, we investigated the in vivo potency of one valmerin. Mice exhibited good tolerance to our lead, which proved its efficacy and clearly blocked tumor growth. Valmerins appear also as good candidates: for further development as anticancer agents.

  DOI：

  10.1021/jm3008536

文献信息

• The use of sulfonylamido pyrimidines incorporating an unsaturated side chain as endothelin receptor antagonists
  作者：Martin H Bolli、Christoph Boss、Martine Clozel、Walter Fischli、Patrick Hess、Thomas Weller

  DOI：10.1016/s0960-894x(02)01084-3

  日期：2003.3

  A series of compounds structurally related to bosentan 1 featuring an unsaturated side chain at position 6 of the core pyrimidine have been studied for their potential to block the ET(A) and ET(B) receptor. Incorporation of a 2-butyne-1,4-diol linker bearing a pyridyl carbamoyl moiety led to in vitro highly potent endothelin receptor antagonists (e.g., 70 and 75). The propargyl derivative 26 significantly

  研究了一系列与波生丹1结构相关的化合物，这些化合物在嘧啶核的6位上具有不饱和侧链，具有阻断ET（A）和ET（B）受体的潜力。掺入带有吡啶基氨基甲酰基部分的2-丁炔-1，4-二醇接头导致体外高效的内皮素受体拮抗剂（例如70和75）。在高血压盐敏感性Dahl大鼠的体内模型研究中，炔丙基衍生物26显着降低了血压。
• [EN] SUBSTITUTED THIOPHENES AND USES THEREOF<br/>[FR] THIOPHENES SUBSTITUES ET LEURS UTILISATIONS
  申请人：ASTRAZENECA AB

  公开号：WO2005016909A1

  公开（公告）日：2005-02-24

  This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical salts, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cancer.

  这项发明涉及具有结构式（I）的新化合物，以及它们的药用盐、组合物和使用方法。这些新化合物可用于治疗或预防癌症。
• [EN] DIARYLUREA COMPOUNDS AND DERIVATIVES AS CHK-1 INHIBITORS FOR THE TREATMENT OF CANCER<br/>[FR] COMPOSES ET DERIVES DE DIARYLUREE UTILISES COMME INHIBITEURS DE CHK-1 DANS LE TRAITEMENT DU CANCER
  申请人：MILLENNIUM PHARM INC

  公开号：WO2003101444A1

  公开（公告）日：2003-12-11

  Disclosed are novel inhibitors of Chk-1 and methods of using the same for therapy.

  揭示了Chk-1的新型抑制剂及其在治疗中的使用方法。
• Chk-1 inhibitors
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US20040014765A1

  公开（公告）日：2004-01-22

  Disclosed are novel inhibitors of Chk-1 and methods of using the same for therapy.

  公开了一种新型的Chk-1抑制剂及其用于治疗的方法。
• N-OXIDES OF DIARYLUREA DERIVATIVES AND THEIR USE AS Chk1 INHIBITORS FOR THE TREATMENT OF CANCER
  申请人：Boyle Robert George

  公开号：US20090270416A1

  公开（公告）日：2009-10-29

  The invention provides a Chk-1 kinase inhibiting compound of the formula (I) or a salt, solvate or tautomer thereof, wherein: G is CH 2 , O, NH, NHCO or CONH; A is a group (CH 2 ) n where n is 1 to 4 provided that when G is O or NH, n is at least 2; X 1 is nitrogen or CH; X 2 is nitrogen or a group CR 5 ; X 3 is nitrogen or a group CR 5 ; X 4 is nitrogen or CH; provided that no more than two of X 2 , X 3 and X 4 are nitrogen; and R 1 ; R 2 ; R 3 ; R 4 ; R 5 and R 6 are as defined in the claims.

  该发明提供了一种Chk-1激酶抑制化合物，其化学式为(I)或其盐，溶剂合物或互变异构体，其中：G为CH2，O，NH，NHCO或CONH; A是( )n基团，其中n为1至4，但当G为O或NH时，n至少为2; X1为氮或CH; X2为氮或CR5基团; X3为氮或CR5基团; X4为氮或CH; 前提是X2、X3和X4中不超过两个为氮; R1、R2、R3、R4、R5和R6如所述。